Literature DB >> 22122999

Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.

Mitsushige Sugimoto1, Masafumi Nishino, Chise Kodaira, Mihoko Yamade, Takahiro Uotani, Mutsuhiro Ikuma, Takahisa Furuta.   

Abstract

BACKGROUND AND AIM: Aspirin enjoys widespread use as an antithrombotic drug, but such ubiquity also increases the risk of gastrointestinal mucosal injury. Recent studies have shown that aspirin can also induce esophageal mucosal injury. We resolved to determine the intragastric pH value necessary to prevent aspirin-induced esophageal mucosal injury.
METHODS: 15 healthy Japanese volunteers were dosed for 7 days in a four-way random crossover trial with 100 mg entero-coated type aspirin only once daily, 100 mg aspirin + 20 mg famotidine twice daily, 15 mg lansoprazole once daily, or 10 mg rabeprazole once daily. All subjects underwent endoscopy and intragastric pH monitoring on day 7.
RESULTS: 7 individuals (46.7%) developed esophageal mucosal injury when ingesting aspirin alone. The incidence of esophageal mucosal injury was reduced however with concomitant dosing of aspirin and famotidine (26.6%; p = 0.193), lansoprazole (0%; p = 0.004), and rabeprazole (6.7%; p = 0.019). Among individuals for whom mean 24-h pH was >5.0 and who experienced pH <4.0 less than 40% of the time, none developed aspirin-induced esophageal mucosal injury.
CONCLUSION: Acid inhibition achieved with a half-dose of a proton pump inhibitor effectively prevented development of aspirin-induced esophageal mucosal injury, whereas a standard dose of a histamine-2-receptor antagonist failed to achieve the same results.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122999     DOI: 10.1159/000329295

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.

Authors:  Mitsushige Sugimoto; Naohito Shirai; Masafumi Nishino; Chise Kodaira; Takahiro Uotani; Shu Sahara; Hitomi Ichikawa; Takuma Kagami; Ken Sugimoto; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2014-07-06       Impact factor: 2.953

Review 2.  Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.

Authors:  Mitsushige Sugimoto; Takahisa Furuta
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

3.  Efficacy of esomeprazole in treating acid-related diseases in Japanese populations.

Authors:  Mitsushige Sugimoto; Takahisa Furuta
Journal:  Clin Exp Gastroenterol       Date:  2012-05-14

Review 4.  Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Front Pharmacol       Date:  2019-01-15       Impact factor: 5.810

5.  Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review.

Authors:  Mitsushige Sugimoto; Jin Seok Jang; Yashiro Yoshizawa; Satoshi Osawa; Ken Sugimoto; Yoshihiko Sato; Takahisa Furuta
Journal:  Diagn Ther Endosc       Date:  2012-07-18

6.  Combination of Xuesaitong and Aspirin Based on the Antiplatelet Effect and Gastrointestinal Injury: Study Protocol for a Randomized Controlled Noninferiority Trial.

Authors:  Bao-Chen Zhu; Chun-Miao Xue; Rui Lang; Wei-Liang Weng; Xu-Jie Wang; Zhen-Zhen Lei; Sha-Sha Zhang; Wen-Hua Yang; Wan-Tong Zhang; Guo-Dong Hua
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.